Gibson CM, Kastelein JJP, Phillips AT, Aylward PE, et al. Rationale and design of ApoA-I event reducing in ischemic syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myoc Am Heart J 2020 Oct 13. pii: S0002-8703(20)30335.
PMID: 33065120